Rio Biopharmaceuticals Inc (Rio Biopharma) is located in Princeton NJ and is a a subsidiary of NC Farma, an international group of pharmaceutical companies headquartered in Brazil
Rio Biopharma and Rio Biofarma Brasil Ltda have collaborated to develop a pipeline of complex generic products including sterile injectable liraglutide and semaglutide.
Rio Biopharma filed an ANDA for semaglutide injectable for diabetes, a generic version of Ozempic©, with the FDA on 21-Dec-2021 and may qualify for 180 days exclusivity upon it’s launch in the USA
Rio Biopharma plans to launch liraglutide 1.2/1.8 mg and 3.0 mg for injection in the USA in 2025 in partnership with Oliva Therapeutics
Chief Executive Officer
Chief Financial Officer
Board Member
Chairman of Board
To contact us please fill in the form below and click SEND
We will respond promptly.
© 2024 Rio Biopharma. All Rights Reserved.